EGFR and non-small cell lung carcinoma: Similarly, a pooled analysis from two phase II studies that included patients with EGFRT790M-positive advanced NSCLC that progressed following treatment with an EGFR TKI showed a CNS relative risk of 54% and disease control rate of 92% [35].